Advertisement
ALC vs TMO
Which Stock Would AI Choose? Alcon Inc. (ALC) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- ALC trades at around $74 with a market cap of $37B, showing relative stability with YTD performance of -6% and a low beta of 0.70 (a measure of volatility relative to the market).
- TMO is larger at $469 per share and $174B market cap, but has faced sharper YTD declines of -19% amid broader market pressures.
- Both stocks operate in healthcare, but ALC's focus on eye care yields lower debt/equity (24%) versus TMO's 83%, indicating reduced financial risk for ALC.
- TMO boasts higher ROE (return on equity, 13.5%) and revenue ($45B TTM) compared to ALC's 4.5% ROE and $10.4B.
- Analyst targets suggest upside: $94 for ALC and $620 for TMO, reflecting growth potential in both amid recent product developments.
- Recent momentum favors ALC's steadier trend versus TMO's volatility from divestitures and expansions.
Introduction
This comparison pits ALC, a specialist in eye care products, against TMO, a diversified leader in life sciences tools and services. Both reside in the healthcare sector, appealing to investors eyeing medical innovation and defensive growth amid volatile markets. Traders focused on relative performance, sector rotation, or long-term positioning in ophthalmology versus broader biotech may find value in analyzing their trajectories, valuations, and catalysts in the current environment.
ALC Overview and Recent Performance
Alcon Inc. (ALC) researches, develops, and sells eye care products worldwide, operating in Surgical and Vision Care segments. Recent market activity has seen its shares trade near the lower end of the 52-week range (71.55-98.56), around $74, with a modest 1-month decline of 0.7%. Sentiment reflects solid Q4 2025 results with 7% sales growth to $2.72B, though EPS of $0.78 missed estimates, alongside board changes, collaborations like with PerZeption Inc., and anticipation for commercial launches. Lower beta (0.70) underscores resilience versus peers.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) leads in analytical instruments, reagents, and services for research, diagnostics, and biopharma. Shares hover at $469 within a wide 52-week range (385.46-643.99), down 3.9% over the past month and 19% YTD, pressured by organic growth challenges. Key developments include Q1 2026 revenue of $11B and EPS beat at $5.44, the opening of a U.S. bioprocess design center, a $1.1B sale of its microbiology unit to Astorg, and dividend hikes, boosting expansion but highlighting portfolio shifts.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from its library of 351 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles—from short-term signals (5min to 60min) to swing trades. Only 25 bots earn a trending spot based on AI-driven relevance to current market conditions like AI infrastructure, semiconductors, and industrials, boasting annualized returns from +23.53% to +163.10%, win rates of 51.30% to 88.33%, profit factors up to 3.33, and drawdowns managed via risk parameters. These virtual and brokerage agents offer copy-trading for real-time opportunities. Explore the Trending AI Robots to align bots with your portfolio.
Head-to-Head Comparison
ALC’s niche in ophthalmology contrasts TMO’s broad life sciences exposure, with ALC prioritizing steady surgical and vision growth drivers versus TMO’s biopharma and diagnostics scale. Recent momentum shows ALC’s milder pullback (-6% YTD) against TMO’s steeper drop, aided by ALC’s lower beta and debt. Valuation trade-offs include ALC’s higher trailing P/E (37.4) but similar forward P/E (~21 vs. 19), while TMO offers superior ROE and revenue scale at the cost of higher leverage. Risk factors tilt toward TMO’s cyclical biopharma sensitivity, while ALC benefits from defensive eye care demand. Market sentiment favors ALC’s outperformance in recent weeks amid sector headwinds.
Tickeron AI Verdict
Tickeron’s AI currently leans toward ALC for its trend consistency, lower volatility (beta 0.70), relative YTD resilience (-6% vs. -19%), and catalysts like product launches in a stable niche—positioning it probabilistically stronger in the near term versus TMO’s scale offset by sharper declines and portfolio adjustments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- ALC’s TA Score: 5 bullish, 3 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +0.06% price change this week, while TMO (@Medical Specialties) price change was -0.73% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
ALC is expected to report earnings on Aug 10, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALC | TMO | ALC / TMO | |
| Capitalization | 32.6B | 174B | 19% |
| EBITDA | 2.54B | 11.7B | 22% |
| Gain YTD | -15.176 | -18.922 | 80% |
| P/E Ratio | 40.03 | 25.80 | 155% |
| Revenue | 10.6B | 45.2B | 23% |
| Total Cash | 1.66B | 3.26B | 51% |
| Total Debt | 5.25B | 43.2B | 12% |
ALC | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 93 | |
SMR RATING 1..100 | 89 | 62 | |
PRICE GROWTH RATING 1..100 | 61 | 54 | |
P/E GROWTH RATING 1..100 | 50 | 47 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as ALC (18) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as ALC (89) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's Price Growth Rating (54) in the Medical Specialties industry is in the same range as ALC (61) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
TMO's P/E Growth Rating (47) in the Medical Specialties industry is in the same range as ALC (50) in the Hospital Or Nursing Management industry. This means that TMO’s stock grew similarly to ALC’s over the last 12 months.
| ALC | TMO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 40% | 3 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 57% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 64% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 61% |
| Advances ODDS (%) | 3 days ago 58% | 14 days ago 62% |
| Declines ODDS (%) | 12 days ago 56% | 3 days ago 63% |
| BollingerBands ODDS (%) | 7 days ago 58% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 63% |
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.